*Disclaimer

RECCE PHARMACEUTICALS LTD (ASX: RCE)

­čöŚ ­čôä ­čôł

RCE: Phase I Clinical Trial Data Review Complete

RECCE PHARMACEUTICALS LTD

2023-07-19 10:08:00

RCE: First Cohort Dosed in Rapid Infusion Phase I/II UTI study

RECCE PHARMACEUTICALS LTD

2023-07-10 10:31:00

RCE: Ethics Approval to Start Phase I/II (I.V.) Clinical Trial

RECCE PHARMACEUTICALS LTD

2023-04-17 10:19:00

RCE: New Family 4 Patent to be Granted for RECCE Anti-Infectives

RECCE PHARMACEUTICALS LTD

2023-04-11 08:29:00

RCE: Recce Receives Further A$973,144 R&D Advance

RECCE PHARMACEUTICALS LTD

2023-04-04 10:08:00

RCE: Recce Selects CMAX for Phase I/II UTI Clinical Trial

RECCE PHARMACEUTICALS LTD

2023-02-20 09:41:00

RCE: Australian Patent to be Granted for RECCE Anti-Infectives

RECCE PHARMACEUTICALS LTD

  1. The Australian Patent Office issued notification of intent to grant RecceÔÇÖs Patent Family 3 ÔÇťAnti -Virus Agent and Method for Treatment of Viral InfectionÔÇŁ
  2. The Australian Patent claims relating to RECCE® 327 (R327) and Anti -Viral formulation RECCE® 529 (R529)
  3. This is the final patent of Family 3 (expiry, November 2037), following those already granted in the biggest pharmaceutical markets in the world such as China, Japan, Europe and Hong Kong

2023-01-10 10:05:00